Alpha Lipoic Acid (ALA)

Alpha lipoic acid (ALA) is a small sulfur-containing molecule your mitochondria make to help convert food into energy. It also happens to be one of the few antioxidants that's both water and fat soluble, meaning it works everywhere in the cell, not just in one compartment, and it regenerates the other big antioxidants (glutathione, vitamin C, vitamin E, CoQ10) once they've been used up. Production declines with age, which is part of why people start supplementing it in their 30s and beyond.

Most people take it for one of three reasons: nerve pain from diabetes (where the evidence is strongest by a wide margin), insulin sensitivity and metabolic support, or general antioxidant and anti-aging use. At 600 mg/day it has roughly two decades of trial data behind it for diabetic neuropathy, including head-to-head comparisons against pharmaceutical options. For everything else, the evidence is thinner but mechanistically coherent. It's cheap, available without prescription in most places, and well tolerated for short-to-medium term use.

Deep-dive

ALA exists in two mirror-image forms: R-ALA (the natural form your body makes) and S-ALA (the synthetic mirror). Most cheap supplements are racemic, a 50/50 mix of both. R-ALA is the biologically active enantiomer that fits the mitochondrial enzymes, S-ALA is essentially filler that doesn't bind the same way and may actually compete for absorption. R-ALA alone is absorbed about 40% better than racemic and produces higher peak plasma levels. That said, the large neuropathy trials almost all used racemic ALA at 600 mg, so don't assume R-ALA at lower doses matches the trial data. Sodium-R-ALA (Na-RALA) is a stabilised form that's substantially more bioavailable again, useful if you want a lower effective dose.

Inside the cell, ALA is reduced to dihydrolipoic acid (DHLA), which is the form that does most of the antioxidant work. The ALA/DHLA pair cycles back and forth, neutralising free radicals and then handing electrons over to recycle glutathione, vitamin C, vitamin E, and CoQ10 from their oxidised back to their active forms. This is the mechanistic reason ALA is often called the "universal antioxidant", it doesn't just neutralise on its own, it keeps the rest of the system running. ALA is also a cofactor for pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase, two enzymes that feed glucose into the citric acid cycle, which is the underlying reason it influences insulin sensitivity and energy metabolism.

Plasma half-life is short, around 30 minutes, but the antioxidant effect persists longer because of tissue redistribution and the recycling of other antioxidants. Oral bioavailability is modest (around 30% for racemic, higher for R-ALA and Na-RALA) and significantly reduced by food, take it on an empty stomach.

Diabetic neuropathy. This is by far the most replicated and clinically meaningful use. The German ALADIN trial series and follow-ups have been running since the 1990s, mostly at 600 mg/day either IV or oral. The SYDNEY 2 trial, a 5-week multicentre RCT in 181 patients, found 600 mg oral ALA significantly improved neuropathy symptoms (pain, burning, numbness, paraesthesia) compared to placebo, with higher doses (1,200 and 1,800 mg) showing more side effects but no extra benefit, 600 mg is the sweet spot. A 4-year extension trial (NATHAN 1) in 460 patients with mild-to-moderate diabetic polyneuropathy found 600 mg/day oral ALA improved neuropathic impairment and muscle strength scores over time, with the strongest effect in patients with normal BMI and tighter glycaemic control. A 2012 meta-analysis of 1,160 patients confirmed clinically meaningful pain reduction in the short term. The overall picture is that 600 mg/day reliably reduces nerve pain and improves nerve function in diabetic neuropathy over weeks to months. It's the most evidence-backed nutritional intervention for this condition by a wide margin, comparable in many trials to gabapentinoids with a cleaner side effect profile.

Insulin sensitivity and metabolic health. A 2018 meta-analysis of 24 trials found ALA significantly lowered fasting glucose, fasting insulin, and HOMA-IR in type 2 diabetics and people with metabolic syndrome, with effects most pronounced at doses of 600 mg or more for at least 8 weeks. Mechanistically, ALA activates AMPK (the same energy sensor berberine and metformin hit) and improves GLUT4 translocation in muscle, so glucose disposal improves without needing more insulin. The effect size is modest compared to metformin or berberine and the trials are mostly short, but for someone with insulin resistance who's already optimising diet and training, it's a reasonable add-on.

Weight and body composition. A 2017 meta-analysis of 12 trials in 534 participants found ALA produced a small but significant reduction in body weight (around 1.3 kg) and BMI versus placebo over 8-24 weeks. Don't take it as a weight loss drug, the effect is meaningful in trials but marginal in real life. Combined with diet, training, and other metabolic levers, it adds a small push.

Lipids and cardiovascular markers. Mixed but mostly favourable. Multiple meta-analyses show modest reductions in LDL, total cholesterol, and triglycerides, with the strongest effect in diabetic and metabolic syndrome populations. ALA also improves endothelial function in trials of patients with metabolic disease, likely through reduced oxidative stress on the vascular endothelium. None of these effects are dramatic on their own, but they're consistent with the broader anti-inflammatory mechanism.

Liver. ALA is part of the standard cocktail for non-alcoholic fatty liver disease (NAFLD) in some clinical protocols, often combined with silymarin or TUDCA. A 2020 meta-analysis found ALA modestly lowered ALT and AST in NAFLD patients alongside its glucose effects. Historically it's also been used in Europe as an adjunct treatment for severe mushroom poisoning (Amanita phalloides), where IV doses can be liver-protective via glutathione regeneration.

Brain and cognition. Animal data is rich, human data is thin. A few small trials in Alzheimer's at 600-900 mg/day have shown modest stabilisation of cognitive decline over 6-12 months, but nothing on the scale of the neuropathy data. ALA crosses the blood-brain barrier and acts on the same mitochondrial machinery there, so the mechanism is plausible. The clearest brain use is the combination with acetyl-L-carnitine, originally proposed by Bruce Ames, as a mitochondrial pair for age-related cognitive decline. The combo has rodent data showing reversal of mitochondrial dysfunction and modest human signal, but it's not yet at the level of evidence the neuropathy story has.

Skin. Topical ALA at 5% in a controlled trial showed modest improvement in skin roughness and fine lines over 12 weeks. Oral ALA contributes to the general antioxidant tone but isn't a dedicated skin compound. If you want skin effects from ALA specifically, the topical route has more direct data.

Women. ALA research has included women throughout, particularly in the diabetic neuropathy, metabolic, and fertility trials. In PCOS specifically, a 12-week trial in 32 women found 600 mg/day improved insulin sensitivity and ovarian response. Several smaller trials combining ALA with myo-inositol report improvements in menstrual regularity and metabolic parameters in PCOS, the inositol-ALA pairing is now a fairly standard component of European PCOS protocols. ALA also lowers serum iron modestly, which can be relevant for menstruating women who tend to run lower on iron stores anyway; check ferritin if you're using it long-term and already on the low end. Pregnancy and breastfeeding: a few small studies have looked at ALA in pregnancy without flagging harm, but routine elective use should still go through an obstetrician.

Older adults. Endogenous ALA production declines with age. Most of the neuropathy and metabolic trials have been in middle-aged to older adults, so this is the population where the effect sizes are largest. The Ames-style ALCAR plus ALA combination was designed specifically with age-related mitochondrial decline in mind.

Limitations of the evidence. Outside of diabetic neuropathy, almost all the trial data is short (8-24 weeks) and in disease populations rather than healthy adults. The long-term effects of daily use in otherwise healthy people are poorly studied. The minerals-binding question (ALA chelates iron, copper, zinc, manganese) is a real but not well-quantified concern. And while the antioxidant cycling story is mechanistically clean, the real-world impact of supplemental ALA on total body redox status in healthy adults is more modest than the marketing suggests.

Dosage:

Diabetic neuropathy: 600 mg/day on an empty stomach. This is the dose used in essentially every positive trial. Higher doses (1,200-1,800 mg) don't add benefit and increase GI side effects. Allow 4-8 weeks for noticeable change in nerve pain and 3-6 months for steady improvement in nerve function

Insulin sensitivity / metabolic support: 600-1,200 mg/day, split into 300-600 mg morning and afternoon doses, taken 30 minutes before meals

General antioxidant / anti-aging use: 300-600 mg/day, one dose in the morning on an empty stomach. Going higher daily isn't useful for healthy people

Hangover or oxidative stress event: 300-600 mg before drinking or before/after a known oxidative load (long flight, intense training, polluted environment). Pairs well with
NAC (N-Acety-L-cysteine) and
Glycine for liver support

Cognitive / mitochondrial stack: 300-600 mg ALA with 500-1,000 mg
Acetyl-L-Carnitine in the morning. The Ames pairing, intended for age-related mitochondrial decline

PCOS: 600 mg/day, typically alongside 2-4 g/day myo-
Inositol. Run for at least 3 months before judging effect

Timing: Empty stomach, ideally 30-60 minutes before food. Food significantly reduces absorption (by roughly 30-50%). If split-dosing, take morning before breakfast and again before lunch. Last dose by mid-afternoon to avoid sleep interference in sensitive people

Forms: Racemic ALA (R/S 50/50) is what most trials used and the cheapest option. R-ALA is about 40% better absorbed and the biologically active form, sensible if you want a lower effective dose or higher peak levels. Sodium-R-ALA (Na-RALA, sold as Bio-Enhanced R-ALA or similar) is the most bioavailable and stable form, roughly 2-3x the bioavailability of racemic, expensive but the best if you're optimising. Avoid extended-release ALA, the data is on immediate-release

Stacks: Natural pair with acetyl-L-carnitine for mitochondrial use, with NAC and glutathione for liver and antioxidant support, with berberine or inositol for insulin sensitivity

Cycling: Not strictly necessary, but if you're using it daily long-term, a 1-2 week break every few months is sensible given the mineral chelation concern

Here's what you can expect:

For diabetic neuropathy, expect a gradual reduction in burning, tingling, and pain over 4-8 weeks, with continued improvement over 3-6 months. It's the most reliable response signal ALA produces. If you have nerve symptoms unrelated to diabetes, results are less predictable.

For insulin sensitivity and metabolic markers, the effect is measured rather than felt. Fasting glucose, fasting insulin, and HOMA-IR tend to drift down over 8-12 weeks of consistent use. You probably won't notice anything subjectively unless your baseline is poor enough that the metabolic improvement translates into more stable energy and clearer thinking through the day.

For general antioxidant or anti-aging use, ALA is a slow-burn compound. You won't feel acute effects. The case for daily use rests on the underlying mechanism (recycling of other antioxidants, AMPK activation, mitochondrial support) rather than a subjective signal. If you're well, well-rested, and don't have a metabolic or neuropathic indication, you'll probably notice nothing. This is the main reason people stop taking it.

Side effects & risks:

GI upset is the most common side effect, especially above 600 mg in a single dose. Nausea, heartburn, abdominal discomfort. Dose-dependent and usually resolves by splitting doses or taking on a fully empty stomach without food directly after

Hypoglycaemia. ALA improves insulin sensitivity, which is the point, but it can drop blood glucose more than expected, particularly if you're on insulin, sulfonylureas, or other glucose-lowering medications. Monitor glucose carefully when starting, especially in diabetics, dose adjustment of diabetes medication may be needed

Insulin autoimmune syndrome (IAS). A rare but serious reaction in which ALA triggers the production of antibodies against insulin, causing severe spontaneous hypoglycaemia. Strongly associated with the HLA-DRB1*04:06 allele, which is much more common in East Asian (especially Japanese and Korean) populations than in Europeans. The condition is reversible on stopping ALA but can cause hospital-level hypoglycaemia. If you're of East Asian ancestry and experience unexplained episodes of severe hypoglycaemia after starting ALA, stop and get a workup

Mineral chelation. ALA binds iron, copper, zinc, and manganese, which is part of the mechanism (it pulls heavy metals out too) but also means it can deplete essential minerals with long-term use. Separate your ALA dose from iron, zinc, copper, or multivitamin doses by at least 4 hours. Check ferritin, serum copper, and serum zinc periodically if you're running it chronically

Thiamine (B1) depletion. Theoretical and reported in case studies. ALA is structurally similar to thiamine and can deplete it with long-term use, particularly in heavy drinkers. Taking a B-complex alongside is a reasonable hedge for anyone running ALA daily for months

Skin reactions. Rare rash, urticaria, or contact-type reactions. Stop if you develop a rash

Sulfur-related smell. Some users get a faint sulfur smell on breath or sweat, particularly at higher doses. Harmless

Thyroid interactions. ALA can compete with thyroid hormone uptake and may modestly suppress T4 to T3 conversion. People on thyroid medication should monitor TSH and free T3/T4 after starting, especially at higher doses

Anticoagulants. Theoretical potentiation of warfarin and other blood thinners through antioxidant and platelet effects. Monitor INR if you're on these

Pregnancy and breastfeeding. Limited safety data despite some small trials in pregnancy showing no harm signal. Skip routine elective use unless directed by an obstetrician

Children. Not enough safety data for routine paediatric use

Long-term safety data. The largest long-term trial (NATHAN 1) ran 4 years at 600 mg/day in diabetic patients with a clean safety profile. Beyond that, chronic high-dose use in healthy people is understudied

🩸

Blood markers

Fasting glucose, fasting insulin, HbA1c, HOMA-IR, baseline if you're using ALA for insulin sensitivity, PCOS, or metabolic indications. Recheck at 8-12 weeks. These are the markers that should move if ALA is doing its job. Diabetics on glucose-lowering medication should monitor more often when starting, since dose adjustments may be needed

Ferritin, serum iron, serum copper, serum zinc, baseline before chronic daily use, especially if you're a menstruating woman or already on the lower end of iron stores. Recheck at 3-6 months. ALA's mineral chelation can drift these down over time

TSH, free T4, free T3, baseline if you're on thyroid medication or have a thyroid history. ALA can interfere with T4-to-T3 conversion modestly

Liver enzymes (ALT, AST, GGT), baseline if you're using ALA for NAFLD or liver support. Falling ALT and GGT are the most reliable signal over 8-12 weeks

HLA-DRB1*04:06 genotyping is worth considering before starting ALA if you're of Japanese or Korean ancestry and plan on long-term use, given the documented IAS risk in this group. Not routine, but the test exists and is informative

For most people using ALA for general antioxidant support at 300-600 mg/day, no specific bloodwork is needed before starting. Baseline matters most for diabetics, anyone running it chronically at 1,200+ mg/day, PCOS use, and anyone of East Asian ancestry who wants to rule out the IAS risk

Sold as a dietary supplement in most countries without prescription. In Germany and a few other European countries, ALA is also available as a prescription medication (Thioctacid) at higher doses for diabetic neuropathy.